Capitalizator.

Capitalize Yourself: Right Data. Real Growth.

Sector Analysis

Pharmaceutical Preparations

Standard Industrial Classification: SIC 2834

Industry Insider Sentiment Analysis

The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.

Filing Date Trade Date Ticker Company Reporting Person Relationship Type Price Qty Total, $ Owned After
2026-11-17 21:15 2026-11-16 MCRB Seres Therapeutics, Inc. Brady Kelly Officer OPT+S $1.38 85 $117 8,775
2026-11-17 21:15 2026-11-16 MCRB Seres Therapeutics, Inc. Shaff Eric D. Director OPT+S $1.38 287 $396 12,936
2026-11-17 21:15 2026-11-16 MCRB Seres Therapeutics, Inc. Henn Matthew R Officer OPT+S $1.38 101 $139 8,132
2026-11-17 21:15 2026-11-16 MCRB Seres Therapeutics, Inc. DesRosier Thomas Officer OPT+S $1.38 103 $142 8,258
2026-11-17 21:30 2026-11-13 CORT CORCEPT THERAPEUTICS INC WILSON JAMES N Director SELL $72.67 10,000 $726,678 1,044,543
2026-11-18 01:42 2026-11-13 KTTA Pasithea Therapeutics Corp. Coastlands Capital LP 10% owner BUY $0.48 1,667,514 $805,910 5,502,549
2026-11-18 01:42 2026-11-16 BOLT Bolt Biotherapeutics, Inc. Coastlands Capital LP 10% owner BUY $5.84 53,094 $309,920 515,510
2026-11-18 01:29 2026-11-16 PTGX Protagonist Therapeutics, Inc MOLINA ARTURO MD Officer SELL $124.65 2,718 $338,799 81,397
2026-11-17 22:17 2026-11-13 RCKT ROCKET PHARMACEUTICALS, INC. Shah Gaurav Officer SELL $2.25 3,020 $6,795 1,053,574
2026-11-17 22:18 2026-11-13 BOLD Boundless Bio, Inc. TANG KEVIN 10% owner BUY $2.40 13,812 $33,149 3,049,379
2026-11-17 22:00 2026-11-16 MIRM Mirum Pharmaceuticals, Inc. Ramasastry Saira Director OPT+S $92.28 2,000 $184,560 0
2026-11-17 22:09 2026-11-13 RCKT ROCKET PHARMACEUTICALS, INC. Wilson Martin Officer SELL $2.25 4,087 $9,196 541,013
2026-11-17 21:48 2026-11-16 UTHR UNITED THERAPEUTICS Corp ROTHBLATT MARTINE A Director, Officer OPT+S $587.74 9,500 $5,583,501 324,443
2026-11-17 21:35 2026-11-13 BBOT BridgeBio Oncology Therapeutics, Inc. Cobo Marc Officer SELL $2.37 78 $185 13,734
2026-11-17 21:05 2026-11-13 KURA Kura Oncology, Inc. WILSON TROY EDWARD Director, Officer BUY $7.52 200,000 $1,504,760 679,194
2026-11-17 21:05 2026-11-13 MAIA MAIA Biotechnology, Inc. Vitoc Vlad Director, Officer, 10% owner BUY $1.00 100,000 $100,000 1,149,121
2026-11-17 21:07 2026-11-13 MAIA MAIA Biotechnology, Inc. Smith Stan Director BUY $1.00 100,000 $100,000 1,619,178
2026-11-17 21:07 2026-11-13 PEPG PepGen Inc. RA CAPITAL MANAGEMENT, L.P. Director, 10% owner BUY $5.00 8,625,000 $43,125,000 27,179,273
2026-11-17 13:30 2026-11-16 CATX Perspective Therapeutics, Inc. Morich Frank Director BUY $0.94 15,000 $14,046 30,000
2026-11-17 11:30 2026-11-16 RNXT RenovoRx, Inc. Agah Ramtin Director, Officer BUY $0.93 50,000 $46,485 848,460
2026-11-16 21:16 2026-11-12 LGND LIGAND PHARMACEUTICALS INC Zimmermann Martine Director SELL $318.17 2,000 $636,336 1,782
2026-11-16 21:11 2026-11-13 DYN Dyne Therapeutics, Inc. Friedl-Naderer Johanna Officer SELL $16.82 231 $3,885 152,666
2026-11-16 21:09 2026-11-13 DYN Dyne Therapeutics, Inc. Kerr Douglas Officer SELL $16.82 2,604 $43,799 167,960
2026-11-16 21:10 2026-11-12 LEGN Legend Biotech Corp Salovey Peter Director BUY $9.16 20,000 $183,250 75,096
2026-11-16 21:10 2026-11-12 KROS Keros Therapeutics, Inc. Prener Anne Director SELL $9.79 574 $5,619 13,212
2026-11-16 21:07 2026-11-13 IMRX Immuneering Corp Gengos Andrew Officer BUY $3.58 25,000 $89,500 250,000
2026-11-16 21:07 2026-11-13 DYN Dyne Therapeutics, Inc. Cox John Director, Officer SELL $16.82 5,513 $92,729 351,994
2026-11-16 21:19 2026-11-12 MRK Merck & Co., Inc. DeLuca Richard R. Officer OPT+S $148.01 58,185 $8,611,875 112,955
2026-11-16 22:33 2026-11-16 LRMR Larimar Therapeutics, Inc. SHERMAN JEFFREY W Director BUY $3.06 3,289 $10,058 8,289
2026-11-16 21:19 2026-11-04 CVSI CV Sciences, Inc. CHEEVER CHARLIE E III 10% owner BUY $0.01 5,440,926 $54,409 32,089,637
2026-11-16 22:33 2026-11-12 ALDX Aldeyra Therapeutics, Inc. DEPTULA-HICKS DARLENE M Director BUY $0.65 7,500 $4,875 7,500
2026-11-17 00:45 2026-11-13 KURA Kura Oncology, Inc. WILSON TROY EDWARD Director, Officer BUY $7.52 200,000 $1,504,760 635,456
2026-11-17 00:13 2026-11-12 BLTE BELITE BIO, INC Scholl Hendrik Peter Officer SELL $165.99 2,000 $331,976 12,500
2026-11-17 00:00 2026-11-12 SEPN Septerna, Inc. Finer Jeffrey Director, Officer OPT+S $43.62 18,500 $807,014 833,909
2026-11-16 23:44 2026-11-16 ORKA Oruka Therapeutics, Inc. Goncalves Joana Officer OPT+S $100.96 7,000 $706,700 31,771
2026-11-16 21:35 2026-11-13 UTHR UNITED THERAPEUTICS Corp ROTHBLATT MARTINE A Director, Officer OPT+S $592.42 9,500 $5,627,991 324,443
2026-11-16 21:24 2026-11-12 LGND LIGAND PHARMACEUTICALS INC KOZARICH JOHN W Director SELL $325.00 500 $162,500 42,122
2026-11-16 21:25 2026-11-13 AUPH Aurinia Pharmaceuticals Inc. Robertson Stephen P. Officer SELL $15.97 11,867 $189,516 576,981
2026-11-16 21:30 2026-11-13 GERN GERON CORP Semerjian Harout Director, Officer BUY $0.95 53,500 $50,825 53,500
2026-11-16 21:30 2026-11-16 GERN GERON CORP Williams Timothy Officer BUY $0.94 12,000 $11,280 12,000
2026-11-16 21:30 2026-11-13 BIVI BIOVIE INC. DO CUONG V Director, Officer BUY $1.16 2,500 $2,906 18,617
2026-11-16 21:31 2026-11-12 VRTX VERTEX PHARMACEUTICALS INC / MA WAGNER CHARLES F JR Officer SELL $547.87 15,286 $8,374,741 31,764
2026-11-16 21:00 2026-11-12 AQST Aquestive Therapeutics, Inc. Davis Matthew W. Officer SELL $3.55 7,197 $25,526 87,500
2026-11-16 21:05 2026-11-12 LFVN Lifevantage Corp BEINDORFF MICHAEL A Director SELL $4.89 10,000 $48,861 31,625
2026-11-16 21:05 2026-11-13 DYN Dyne Therapeutics, Inc. Lucera Erick Officer SELL $16.82 1,991 $33,489 117,775
2026-11-16 15:30 2026-11-12 PHIO Phio Pharmaceuticals Corp. Deming David H Director BUY $0.82 12,000 $9,823 61,800
2026-11-16 14:45 2026-11-12 CTTH CTT PHARMACEUTICAL HOLDINGS, INC. CTT PHARMACEUTICAL HOLDINGS, INC. Director, Officer BUY $0.05 1,500 $81 9,454,036
2026-11-16 13:30 2026-11-12 CATX Perspective Therapeutics, Inc. Woods Lori A Director BUY $0.84 23,750 $20,040 28,557
2026-11-16 13:30 2026-11-12 CATX Perspective Therapeutics, Inc. Williamson Robert F III Director BUY $0.84 24,898 $20,904 115,271
2026-11-16 13:30 2026-11-12 CATX Perspective Therapeutics, Inc. Morich Frank Director BUY $1.00 15,000 $14,957 15,000
SHOW ENTRIES

Sector-Wide Insider Alpha

Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.

SEC Filings in Pharmaceutical Preparations

Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.

UNDERSTANDING THE DATA

FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.

TRADE DATE: The actual day the insider executed the purchase or sale in the market.

INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.

OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.

CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.

TRADE TYPES DEFINITIONS

BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.

SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.

OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.